

Invited Mini Review

Interleukin-32: Frenemy in cancer?

Sora Han¹ & Young Yang^{2,*}¹Research Institute for Women's Health, ²Department of Biological Sciences, Sookmyung Women's University, Seoul 04310, Korea

Interleukin-32 (IL-32) was originally identified in natural killer (NK) cells activated by IL-2 in 1992. Thus, it was named NK cell transcript 4 (NK4) because of its unknown function at that time. The function of IL-32 has been elucidated over the last decade. IL-32 is primarily considered to be a booster of inflammatory reactions because it is induced by pro-inflammatory cytokines and stimulates the production of those cytokines and vice versa. Therefore, many studies have been devoted to studying the roles of IL-32 in inflammation-associated cancers, including gastric, colon cancer, and hepatocellular carcinoma. At the same time, roles of IL-32 have also been discovered in other cancers. Collectively, IL-32 fosters the tumor progression by nuclear factor- κ B (NF- κ B)-mediated cytokines and metalloproteinase production, as well as stimulation of differentiation into immunosuppressive cell types in some cancer types. However, it is also able to induce tumor cell apoptosis and enhance NK and cytotoxic T cell sensitivity in other cancer types. In this review, we will address the function of each IL-32 isoform in different cancer types studied to date, and suggest further strategies to comprehensively elucidate the roles of IL-32 in a context-dependent manner. [BMB Reports 2019; 52(3): 165-174]

INTRODUCTION

Interleukin 32 (IL-32) was initially identified in activated natural killer (NK) and T cells, and its expression is strongly augmented by microbes, mitogens, and other pro-inflammatory cytokines. Accumulating evidences has shown that IL-32 is an amplifier of inflammation through its stimulatory effects on pro-inflammatory cytokines, including IL-1 β , IL-6, and tumor necrosis factor α (TNF- α). Thus, it is likely that prolonged or over-activation of IL-32 would play a role in some chronic inflammation-related diseases, including rheumatoid arthritis (RA), Crohn's disease, and cancer. Indeed, since many studies

have uncovered the molecular mechanisms by which IL-32 exerts anti-tumor or pro-tumor effects, it is appropriate to summarize the detailed functions of IL-32 in various cancers to understand a precise role of IL-32, and to present the direction for future research. Thus, we will review the effects of IL-32 on various cancers in three aspects: first, a role of IL-32 in tumors which are highly related to inflammation; second, a role of IL-32 in tumors which are not related to inflammation; and lastly, effects and functions of IL-32 in pro- or anti-tumor immune cells.

ROLES OF IL-32 IN INFLAMMATORY CANCERS

Development of malignant tumors follows a dynamic sequential progression that includes initiation, malignant conversion, and metastasis. As tumor mass increases progressively, tumor cells need to communicate with components of the tumor microenvironment for maintenance of tumor mass, consisting of infiltrating immune cells and stromal cells. Interactions between tumor and immune cells in tumor development are also crucial factors of the tumor microenvironment (1). Therefore, tumor infiltrating immune cells are considered accurate independent prognostic factors, superior to tumor node metastases (TNM) tumor stage (2). The most common subsets of tumor infiltrating lymphocytes (TILs) are clusters of CD3⁺, CD4⁺, CD8⁺, and Forkhead box P3⁺ (Foxp3⁺) T lymphocytes. CD4⁺ T lymphocytes were classified into Th₁ and Th₂ cells in the early 1980s, based on different T cell functions (3). Th₁ cells promote the toxic effects of cytotoxic T lymphocytes (CTLs) and Th₂ cells enhance the antibody-mediated humoral immune response. Recently, CD4⁺Foxp3⁺-expressing T lymphocytes were identified as regulatory T lymphocytes (Treg). Tregs play a role in suppressing the immune system and promoting cancer progression (4). Therefore, it is conceivable that several cancers are caused by chronic infection and inflammation, after acquiring various harmful genetic alterations. Chronic inflammation of the esophagus can increase incidence of esophageal carcinoma (5). Cirrhosis and inflammation of the liver can develop into hepatocellular carcinoma (6). Chronic pancreatitis increases the incidence rate of pancreatic cancer (7). Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC) have been linked to the development of colon adenocarcinoma (8). Since IL-32 expression is increased in inflammatory diseases, such as IBD

*Corresponding author. Tel: +82-2-710-9590; Fax: +82-2-2077-7322; E-mail: yyang@sookmyung.ac.kr

<https://doi.org/10.5483/BMBRep.2019.52.3.019>

Received 19 November 2018

Keywords: Apoptosis, Cancer stem cell (CSC), Inflammatory cancer, Interleukin 32 (IL-32), Natural killer (NK) cell, Women's cancer

and RA, and amplifies inflammatory cytokines, it is conceivable that IL-32 is strongly associated with various cancers related to inflammation.

Gastric cancer (GC)

Even though most infected individuals remain asymptomatic throughout their life (9), infection with *Helicobacter pylori* (*H. pylori*) causes chronic gastric inflammation. Approximately 10% of *H. pylori*-infected individuals have been reported to develop peptic ulcer disease and 1 to 3% of them progress to GC (10). IL-32 expression in sera from 16 GC patients was first detected using an IL-32 enzyme linked immunosorbent assay (ELISA), and IL-32 was slightly increased compared to 10 healthy donors. IL-32 expression was highly increased in the gastric mucosa from GC patients, while it was rare in healthy gastric mucosa (11, 12), but the increased amount of IL-32 was mainly localized in the cytoplasm of gastric epithelial cells from gastritis and GC patients (11).

Several isoforms of IL-32 can be generated through alternative splicing (13, 14). The complete transcript that contains all exons is IL-32 γ . IL-32 γ mRNA can be spliced to produce shorter isoforms, including IL-32 α , IL-32 β , and IL-32 δ (15-17). Other isoforms of IL-32 have not been well-studied yet. These isoforms show context-dependent function. For example, IL-32 γ and IL-32 β have been shown to induce caspase-8-dependent apoptosis in thyroid cancers (16), but not in breast cancers (18). Human gastritis tissue, as well as a gastric cancer cell line AGS cells expressed mostly IL-32 β and marginally IL-32 ϵ , without detection of other isoforms (11). *H. pylori* infection increases in the cytoplasmic IL-32 expression in AGS cells were found to be dependent on the bacterial cytotoxin-associated gene pathogenicity island (cagPAI) genes, a cluster of approximately 30 genes, which critically influences the progression of GC. The cagPAI-mediated IL-32 production depended on nuclear factor kappa B (NF- κ B) activation (11). However, phosphorylation of NF- κ B was not observed in AGS cells treated with recombinant IL-32 β . Thus, IL-32 β is considered to have a specific intracellular function in GC tissue or GC-derived immortal cells, instead of a paracrine function (11). Indeed, *H. pylori* infection-induced IL-8, C-X-C motif chemokine 1 (CXCL1), CXCL2, and TNF- α production was impaired in IL-32 deficient AGS cells (11). On the other hand, a single nucleotide polymorphism (SNP) in the IL-8 gene, which is associated with increased IL-8 expression, was identified as a risk factor for GC in the Japanese population (19). Considering that IL-32 β increases IL-8 production, it is a possible that IL-32 β overexpression in GC may be associated with GC carcinogenesis. Wang *et al.* performed genetic analyses and found that a SNP in IL-32 β itself was associated with GC carcinogenesis. The study showed a positive relationship between a SNP on IL-32 rs2015620 in the Chinese population and GC (20).

In addition to the possibility that IL-32 β is associated with GC carcinogenesis, the role of IL-32 in GC progression and

metastasis was also revealed by analysis of 120 patients diagnosed with GC (21). Cytoplasmic IL-32 expression was stronger in malignant stages of GC, and IL-32 β was the major isoform found, with minor expressions of IL-32 α and IL-32 γ . Moreover, both IL-32 isoforms were highly expressed in patients with invaded serosal surface of the gastric walls and lymph node metastasis. This study supports the possibility that IL-32 could be a prognostic marker for GC. The underlying molecular mechanism of IL-32 on GC invasion has also been elucidated. Human GC TSGH9201 cells overexpressing IL-32 γ showed increases in both intra- and extracellular levels of IL-32 β , and augmented migration and invasion capacities. Furthermore, increased activation of AKT- β -catenin signaling pathway by IL-32 β was accompanied by increased production of IL-8, vascular endothelial growth factor (VEGF), and active matrix metalloproteinase 2 and 9 (MMP2 and 9) (15). Clarification is needed regarding whether this IL-32 β -mediated GC invasion is mediated by intra- or extracellular IL-32 or both. Although several studies showed the positive relationship between expression levels of IL-32 and metastasis and invasion of GC in patients (21, 22), one study showed that IL-32 had a non-significant relationship with the GC malignancy marker TNF- α in patients with GC (23). This discrepancy suggests that experiments with a larger GC patient population are needed in future studies.

In general, tumor infiltrating immunosuppressive cells, including tumor associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), and Tregs are correlated with poor GC prognosis, whereas immune activator and effector cells, including CTL, dendritic cells (DCs), and CD45RO memory T cells are associated with an improved GC prognosis. Those immune cells affect the progression and malignancy of GC as they produce and secrete various immunoregulatory soluble factors into the tumor micro-environment. Chang *et al.* reported that high levels of IL-32, along with IL-6, IL-10, C-C motif chemokine ligands (CCL) 7, and CCL21 were observed in the sera of GC patients and were associated with poor prognosis (24). Although functions of extracellular and circulating IL-32 in GC cells were not investigated in that study, it is a quite possible that circulating IL-32 performs a functional role in immune cells in the tumor microenvironment, considering that circulating IL-32 positively regulates pro-inflammatory cytokines, including IL-1, IL-6, and TNF- α .

Collectively, *H. pylori* infection-induced IL-32 β was the major isoform found in GC and the resultant IL-32 β stimulated the production of various cytokines, including IL-8, CXCL1, CCL21, MMP2/9, and TNF- α . These inflammatory cytokines would be associated with GC carcinogenesis and invasion. However, extracellular IL-32 β did not affect cytokine production in AGS cells (11). Therefore, further studies are needed to determine whether extracellular IL-32 β could affect the properties of GC cells using various GC cell lines.

Pancreatic cancer

IL-32 is more highly expressed in inflamed lesions of chronic pancreas, compared to those in normal pancreatic duct cells. In addition, a strong expression of IL-32 has been observed in pancreatic cancer tissues. Pro-inflammatory cytokines IL-1, interferon γ (IFN- γ), and TNF- α stimulated IL-32 production in pancreatic cancer cell lines, including PANC-1, MIA PaCa-2, and BxPC-3 cells, which weakly express IL-32 without inflammatory stimulation. Activation of the phosphoinositide 3-kinase (PI3K)-Akt signaling pathway was required to induce IL-32 expression by those cytokines. Inhibition of NF- κ B and activated protein-1 (AP-1) signaling pathways markedly suppressed the IL-1, IFN- γ , and/or TNF- α -induced IL-32 mRNA expression (25). Collectively, IL-32 expression was induced by PI3K-Akt signaling pathway-dependent NF- κ B-AP-1 signaling activation. Since small interfering IL-32 RNA (siIL-32) reduced pro-survival proteins (B cell lymphoma 2, Bcl-2; B cell lymphoma extra large, Bcl-xL; and myeloid cell leukemia sequence 1 protein, Mcl-1) without changing pro-apoptotic proteins (Bcl-2 associated X protein, Bax; Bcl-2 antagonist killer 1, Bak; BH3 interacting domain death agonist, Bid; Bcl-2 associated death promoter, Bad), IL-32 is likely to promote growth and survival of pancreatic cancer cells. On the other hand, a functional isoform of IL-32 in pancreatic cancer cell has not been reported. Therefore, further studies are needed to determine the isoform of IL-32 responsible for pro-survival effects in pancreatic cancer cells.

Colon cancer

The risk of colorectal cancer (CRC) is positively proportional to the extent and duration of IBD, such as UC and CD (26). Since IL-32 is a pro-inflammatory cytokine and CRC is one of well-known inflammation-induced cancers, the effect of IL-32 on CRC was determined in an azoxymethane (AOM)-induced CRC model using human IL-32 α transgenic (TG) mice. The expression of IL-32 α showed protective effects on AOM-induced CRC incidence (27). The underlying mechanism was reported that the induction of TNF receptor 1 (TNFR1) expression by IL-32 α in tumors, which causes apoptosis of tumor cells. Even though the IL-32 gene is not found in rodents, human IL-32 α seems to be able to induce the apoptotic death of mouse tumor cells. This result suggests a role for human IL-32 in the mouse cells. The study also confirmed that TNF- α induced cell death in IL-32 α -expressing human SW620 colon cancer cells. IL-32 α induced sustained c-Jun N-terminal kinases (JNK) activation via reactive oxygen species (ROS) production, resulting in the apoptotic death of SW620 cells. A relationship between IL-32 α and TNFR1 has also been suggested from studies of tumor tissue from CRC patients, where IL-32 α and TNFR1 were co-expressed. Expression of IL-32 α and TNFR1 increased until CRC reached stage II, and decreased in stage III and IV. This suggests that IL-32 α exerts suppression of CRC growth at the initial stage of tumor progression. On the other hand, why and how IL-32 α expression decreases as CRC stage

progresses remains to be investigated. In a study by Yun *et al.*, a single injection of AOM induced CRC, without subsequent dextran sodium sulfate (DSS) treatment. Since AOM is a genotoxic chemical and used for initiation of genomic mutations, a single intraperitoneal injection of AOM is usually followed by a 1-week exposure to 2% DSS in the drinking water, and results in a 100% incidence of colonic adenocarcinoma (28). Therefore, the protective effect of IL-32 α against CRC growth is not likely due to an inflammatory mechanism, because the mice were not co-treated with DSS, which is a non-genotoxic chemical that induces a reproducible inflammation (29). Therefore, the AOM-DSS-induced CRC model can provide answers on how the inflammatory function of IL-32 α affects tumor growth, and which inflammatory cells are recruited into the tumor mass. Contrary to the study of Yun *et al.*, Yang *et al.* investigated whether IL-32 expression has clinical significance in CRC metastases using a total of 70 CRC patients, including 47 cases of single CRC organic metastasis lesions. They found that IL-32 expression increased in the organic metastasis and the lymph node metastasis of CRC. Thus, IL-32 expression is likely to stimulate the organic metastasis and the lymph node metastasis of CRC (30). Interestingly, recent reports have suggested that IL-32 θ would have anti-CRC effects through its anti-inflammatory function (31), while others have shown it to be a CRC inducer under obesity-induced inflammation conditions (32). To resolve this discrepancy, further analysis on larger populations is required and it should be determined which IL-32 isoform is involved in metastases of human CRC patients.

Hepatocellular carcinoma

Hepatic fibrosis is initiated upon hepatocyte damage, followed by the recruitment of inflammatory cells and can further progress to chronic liver diseases and cirrhosis, and even to hepatocellular carcinoma (HCC) (33). Hepatic fibrosis is characterized by the progressive accumulation of extracellular matrix (ECM) secreted by hepatic stellate cells (HSCs), and the balance between ECM production and degradation, mediated by matrix metalloproteinases (MMPs), and endogenous inhibitors of metalloproteinases (TIMPs). IL-32 induces cytokines, including IL-1 β , IL-6, IL-8, and TNF- α . (34, 35), which are highly increased in the liver with severe fibrosis (34, 36, 37). Moreover, recombinant IL-32 γ treatment of LX-2 cells, an ECM-producing human hepatic stellate cell line, was enough to induce TIMP-1 expression by activation of the AP-1 signaling pathway (34). Moreover, the increase of TIMP-1 expression promoted the migration of LX-2 cells. In that study, the authors suggested that IL-32 might be a new therapeutic target for hepatic fibrosis as well as hepatitis, because hepatitis B virus (HBV) and hepatitis C virus (HCV) infections could induce IL-32 expression, as well as liver fibrosis in hepatocytes (38, 39).

IL-32 α levels in the tumor region from patients with HCC were markedly higher than in the non-tumor region, and HCC

patients also showed high levels of circulating IL-32 α levels (40, 41). In tumor tissue, IL-32 α localized in the cytoplasm and IL-32-expressing tumor cells were located at the invasion site of blood vessels. IL-32 α stimulated cell survival and growth through NF- κ B activation and maintenance of the Bcl-2 anti-apoptotic protein in the SK-Hep1, HCC cell line. Additionally, tumor promoting activity of IL-32 α was confirmed using an HCC xenograft mouse model with various cell lines. One study investigated whether IL-32 would be an accurate marker for early diagnosis of HCC using 50 HCC patients and 15 healthy volunteers (42). The mean serum level of IL-32 was higher in patients with HCC than in the control subjects ($P < 0.001$), but did not correlate with survival rate. Those experimental data support IL-32 as a prospective diagnostic marker for HCC along with alpha-fetoprotein (AFT) and IL-18, but not as a prognostic marker. Further studies are needed to determine the levels of IL-32 in the sera of patients with HCC, cirrhosis, and stage-dependent HCC patients to validate the possible application of IL-32 as an early diagnosis marker for HCC. Recently, Kim *et al.* reported that IL-32 γ showed anti-viral effects against HBV. Intracellular IL-32 γ inhibited the transcription and replication of HBV through non-cytopathic pathway in hepatocytes (43). Therefore, further investigation of this novel effect of IL-32 γ on HBV clearance in the carcinogenesis of hepatocytes is needed.

Lung cancer

Initiation and progression in lung cancer, as in other cancers, are primarily driven by genetic alterations (44) and are strongly linked to inflammation. IL-32 expression is highly up-regulated in most adenocarcinomas, but not in squamous-cell carcinomas (SCC). IL-32-expressing TILs, mainly composed of CD68⁺ macrophages, CD4⁺ T lymphocytes, and dendritic cell (DC)-specific intracellular adhesion molecule-3-grabbing non-integrin DC (DC-SIGN⁺), and IL-32-expressing tumor cells are frequently observed in lymph node metastases, along with IL-6, IL-8, and VEGF (45, 46). Thus, it is likely that IL-32 significantly correlates with lung tumor progression stages, lymph node and distant metastases with poor prognosis (45). IL-32 expression is associated with acquisition of an invasive and metastatic phenotype of lung cancers. As an underlying mechanism, amplification of the loop of IL-32 and NF- κ B is related with enhanced migration via up-regulation of MMP2/9. On the other hand, IL-32 polymorphisms (rs12934561 and rs28372698) are closely associated with poor survival in SCC, and with poor prognosis in moderate and well-differentiated lung cancer patients (47). On the other hand, Yun *et al.* recently reported on the tumor-suppressive effect of IL-32 γ in the lung (48). In this study, mice overexpressing IL-32 γ showed a suppressive effect on growth of carcinogen-induced lung tumors with increased TIMP-3 and reduced NF- κ B activity. Additionally, expression levels of both IL-32 and TIMP-3 were decreased in the lung cancer tissues compared to normal lung tissues. These discrepant roles of IL-32 in the pathogenesis of

lung cancer are presumed to be due to the different reactivity of IL-32 to various carcinogens, as well as the different roles of extra- and intracellular IL-32. This discrepancy should be further elucidated. The up/downstream signaling pathways of IL-32 in inflammatory cancers are summarized in Fig. 1.

ROLE OF IL-32 IN OTHER TYPES OF CANCER

Women's cancer

Breast cancer: We previously reported that IL-32 β and IL-32 γ mRNAs were highly increased in MDA-MB-231 malignant breast cancer cells, but only that IL-32 β protein was detected by Western blotting (49), consistent with a previous report showing that IL-32 γ mRNA splices into IL-32 β , followed by mainly expression of IL-32 β protein (15). The expression level of IL-32 β was positively correlated with tumor volume, metastasis to lymph nodes, and tumor stage. MDA-MB-231 cells expressing IL-32 β exhibited increased migration and invasion capacities, with increases in epithelial mesenchymal transition (EMT) markers, including vimentin and slug. As an underlying signal transduction mechanism, we showed that IL-32 β enhanced migration and invasion through increase of soluble factor VEGF production by signal transducer and activator of transcription 3 (STAT3) activation. Later, Wang *et al.* also showed that tumor growth was increased with




Fig. 1. Biological functions of IL-32 in inflammatory tumors. Different colors indicate each cancer type and cancer type specific signaling pathway. AOM: azoxymethane, ROS: reactive oxygen species, JNK: c-Jun N-terminal kinases, NF- κ B: nuclear factor kappa B, TIMP: tissue inhibitors of metalloproteinase, MMP: matrix metalloproteinase, *H. pylori*: *Helicobacter pylori*, cagPAI: cytotoxin-associated gene pathogenicity island, HBV: hepatitis B virus, HCV: hepatitis C virus, VEGF: vascular endothelial growth factor, CXCL: C-X-C motif chemokine, CCL: C-C motif chemokine ligands, TNF- α : tumor necrosis factor α , PI3K: phosphoinositide 3-kinase, AP-1: activated protein 1.

administration of recombinant IL-32 protein to MDA-MB-231 tumor-bearing mice, and that IL-32 increased proliferation of MCF-7 cells and inhibited apoptosis induced by serum starvation (18). On the other hand, since IL-32 enhances VEGF production under hypoxic conditions in breast cancer, it is conceivable that IL-32 β is regulated by hypoxia. Indeed hypoxia induces IL-32 β production through ROS production (50), which was proven by showing that IL-32 β production was suppressed by both nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and mitochondrial ROS inhibitors. Under normoxic conditions, IL-32 β interacts with the Von Hippel-Lindau (VHL) E3 ligase complex, independent of hydroxylation of IL-32 β . Thus IL-32 is degraded through ubiquitination. In hypoxic-conditioned cells, hypoxia-induced ROS disrupts the interaction between VHL and IL-32 β , leading to accumulation of IL-32 β (50).

The pro-inflammatory cytokines IL-1 β and IL-18 are important amplifiers of the inflammatory process with IL-32. These cytokines are produced as pro-IL-1 β and pro-IL-18 and inflammasomes facilitate maturation of pro-IL-1 β and pro-IL-18 under infection and tissue damage conditions. Without inflammasome signals, pro-IL-1 β is degraded through ubiquitination. Upon generation of an activation signal, it is de-ubiquitinated and processed into its mature form (51). IL-32 β is another interleukin which is regulated by ubiquitination.

On the other hand, hypoxia-induced IL-32 β interacts with protein kinase C δ (PKC δ) and this interaction results in the suppression of PKC δ -induced apoptosis (52). We also showed that the accumulated IL-32 β translocates to the mitochondria under hypoxic conditions. To investigate the role of mitochondrial IL-32 β , metabolic alteration was examined. The hypoxia-induced IL-32 β enhanced glycolysis through activation of lactate dehydrogenase through the sustained activation of proto-oncogene tyrosine-protein kinase Src (50). This was the first report showing that IL-32 β plays a role in the regulation of breast cancer cell metabolism. A recent report suggested that IL-32 is a prospective therapeutic target for triple negative breast cancer, since IL-32 was more highly expressed in cancer tissue from patients with triple negative breast cancer (53), implying a critical role of IL-32 in the progression of the breast cancer.

Cervical cancer: IL-32 was highly expressed in tissues showing classical morphological features of human papillomavirus (HPV) infection, including koilocytosis, acanthosis, and papillomatosis from cervical cancer patients, but not in tissues lacking HPV-associated nuclear atypia. However, IL-32 expression did not correlate with survival rates of cervical cancer patients. When HPV E7 oncoprotein was induced in cervical cancer cells, such as SiHa and C33A cells, IL-32 expression was induced by cyclooxygenase 2 (COX2), which is an enzyme producing inflammatory mediators, and suppression of COX2 failed to induce IL-32 by HPV E7 oncoprotein (54). Interestingly, IL-32 γ overexpression inhibited E7 oncoprotein and COX2 expressions in SiHa and CaSki

cells. These results imply that E7-induced IL-32 γ suppresses E7 and COX2 expression by a negative feedback loop. In addition, Lee *et al.* showed that IL-32 overexpression increased the levels of p21 and cleaved-poly ADP-ribose polymerase (PARP), as well as the suppression of cyclin E and cyclin A expression. Thus, HPV infection-induced IL-32 may contribute to the inhibition of tumorigenesis in cervical cancer cells (55). On the other hand, IL-32 β expression was increased in T cells undergoing activation-induced cell death, and inducible expression of IL-32 in a HeLa human cervical cancer cell line caused apoptosis, while IL-32 knockdown inhibited apoptosis (56). In addition, phospholipase A2-activating protein (PLAA) enhanced cisplatin-induced apoptosis in HeLa cells and cisplatin induced IL-32 expression in cells expressing high PLAA (57). Contrary to its role in GC, IL-32 β is involved in the apoptosis of cervical cancer.

Lymphoma

Gastric B-cell lymphoma: IL-32 and COX2 expressions were immunohistochemically detected in 31 primary gastric B-cell lymphoma patients and 19 chronic gastritis patients, and were significantly higher in *H. pylori*⁺ lymphoma tissues compared with *H. pylori*⁻ lymphoma tissues (58). This is reasonable because an increase in COX2 in the human stomach is associated with *H. pylori* infection (59, 60) and COX2 increases IL-32 expression (61). Cui *et al.* also showed (58) that IL-32 and COX2 expressions were significantly correlated with greater *H. pylori* infection, more frequent lymph node metastasis, and advanced stages of gastric B-cell lymphoma. In addition, patients with higher COX2 and IL-32 levels showed a poorer prognosis compared with those patients with lower COX2 and IL-32 levels, but the difference was not statistically significant. On the contrary, high levels of IL-32 could inhibit HPV-induced tumorigenesis, and increases in COX2 and IL-32 seem to be associated with poor prognosis of gastric B-cell lymphoma. This is another example showing that IL-32 exerts context-dependent function.

Cutaneous T-cell lymphoma (CTCL): Cutaneous T-cell lymphoma (CTCL) is characterized by clonal expansion of malignant T-cells, and the most common type of CTCL is mycosis fungoides (MF). MF progresses from flat erythematous patches to the tumor stage by expansion of malignant T-cells. An *in silico* approach involving meta-analysis revealed specific genes for MF tumor stages, which were expressed at significantly higher levels in MF and showed that MF originates from IL-32-producing cells (62). In addition, Suga *et al.* showed that serum IL-32 levels were positively correlated with disease activity within individual CTCL patients. Keratinocytes express IL-32 in the skin of MF patch and plaque, whereas in MF tumor, atypical T cells do. Thus it is clear that both tumor and stromal cells express IL-32. A study also revealed that IL-32 stimulated proliferation of a MF cell line, MyLa and Sezary syndrome cell line, and SeAx cells through mitogen-activated protein kinase (MAPK) and NF- κ B

activation, without inducing apoptosis (63). Since the addition of anti-IL-32 antibodies to culture inhibited the proliferation of SeAx cells and the viability of MF cells, it is likely that IL-32 serves as an autocrine, as well as paracrine cytokine in CTCL. This study clearly shows that circulating IL-32 can directly affect tumor cells. The up/downstream signaling pathways of IL-32 in non-inflammatory cancers are summarized in Fig. 2.

EFFECT OF IL-32 ON CANCER-RELATED IMMUNE CELLS

IL-32 enhances NK cell sensitivity and cytotoxicity against tumor cells

IL-32 was originally identified as a cytokine produced and secreted from NK cells and NK cells are well known innate immune cells which display tumor-killing capacity. Thus, it is conceivable that IL-32 affects tumor growth by modulating NK cell activity. Indeed, Cheon *et al.* reported that IL-32 α overexpressing chronic myeloid leukemia (CML) cells, including K562, Kcl22, and BV173, were highly susceptible to NK cell-mediated killing. This enhanced susceptibility to NK cells was due to IL-32 α -stimulated increases in Fas and UL16-binding protein 2 (ULBP2) via activation of p38 MAPK in CML cells (64). Both Fas and ULBP2 are key players associated with NK cell cytolytic activity. NK cells expressing Fas ligand (FASL) effectively eliminate tumors expressing Fas. ULBPs are the most typical ligands of the natural killer group 2D (NKG2D), which is a critical activating receptor on the

surface of activated NK cells (65, 66). Thus, tumor cells expressing ULBPs are susceptible to activated NK cells. Further study are needed to determine whether IL-32 α can also induce death signal receptors in other cancer types. In addition to the effect of IL-32 α on enhancement of tumor cell sensitivity against NK cells, Park *et al.* showed that IL-32 also enhanced NK cell cytotoxicity (67). Co-incubation of a human NK cell line NK-92 cells with PC3 prostate cancer cells or SW620 colon cancer cells showed a significant inhibition of tumor cell growth. The death receptor TNFR2 and death receptor 3 (DR3) were upregulated in PC3 cells, and both FAS and DR3 were also increased in SW620 cells by co-culture of PC3 cells with NK-92 cells, leading to susceptibility to NK-mediated killing. However, IL-32 deficient NK-92 cells failed to induce expression of death receptor on tumor cells. It is known that TNF-related apoptosis-inducing ligand (TRAIL), TNF, FASL, and DR3 ligand (also known as APO3L) are released by NK-92 cells and induce cancer cell death (68, 69). Thus, Park *et al.* showed that expression of DR3 ligand in NK cells was upregulated in NK-92 cells after co-culture of NK cells with cancer cells, and inhibited by IL-32 siRNA treatment (67). Additionally, NK cells eliminated the tumor cells through cytotoxic perforin/granzyme-containing granule exocytosis and the nitric oxide (NO), but IL-32 did not affect this pathway. How IL-32 is involved in increasing the DR3 ligand on NK cells and its death receptor on tumor cells should be the topic




Fig. 2. Biological functions of IL-32 in non-inflammatory tumors. Different colors indicate each cancer type and cancer type specific signaling pathway. *H. pylori*: *Helicobacter pylori*, COX2: cyclooxygenase 2, ROS: reactive oxygen species, HPV E7: human papillomavirus E7 oncoprotein, PARP: poly ADP-ribose polymerase, VEGF: vascular endothelial growth factor, pSTAT3: phosphorylated signal transducer and activator of transcription 3, PKC δ : protein kinase C δ .




Fig. 3. IL-32 affects both tumor growth and death by modulating immune cells. (A) IL-32 stimulates tumor and NK cells to facilitate tumor cell killing. Expression levels of NK cell target proteins, including FAS and ULBP are upregulated in IL-32 α -expressing CML (upper). IL-32-expressing NK cells secrete the ligands for DR3 and TNFR2, DR3 and TNF, respectively (bottom). (B) IL-32-expressing tumor cells recruit anti-tumoral NK cells and CTLs, while IL-32 also stimulates the differentiation of immunosuppressive CD11c⁺ mDC and CD163⁺ CD68⁺ M Φ . FASL: Fas ligand, ULBP2: UL16-binding protein 2, NKG2D: natural killer group 2D, CML: chronic myeloid leukemia, NK cell: natural killer cell, TNFR2: tumor necrosis factor receptor 2, DR3: death receptor 3, CTL: cytotoxic T lymphocytes, M Φ : macrophages, mDC: mature dendritic cells.

of future studies. Collectively, IL-32 affected NK cell cytotoxicity and susceptibility of tumor cells to NK cells (Fig. 3A).

IL-32 recruits CTLs and NK cells into tumor mass

To determine a systemic role of IL-32, Yun *et al.* generated IL-32 β TG mice in which circulating IL-32 levels were increased (70). Interestingly, IL-32 β TG mice showed attenuated growth of subcutaneously implanted B16 melanoma with increased pro-apoptotic genes. This suggests circulating IL-32 β directly induced apoptosis of B16 melanoma cells. Using a CRC xenograft model of SW620 cells and prostate cancer cells (PC3) expressing IL-32 β , tumor growth and mass were reduced, and the number of CTLs and NK cells in blood, spleen, and solid tumor was increased. This implies that IL-32 β could play a role in the tumor microenvironment.

Oh *et al.* also generated IL-32 γ TG mice and observed that B16 melanoma growth was suppressed in IL-32 γ TG mice. In addition, IL-32 γ -overexpressing colon cancer cells showed inhibition of tumor growth in a xenograft model. The inhibitory effect of IL-32 γ on tumor growth was associated with the suppression of constitutively activated NF- κ B and STAT3 in tumor tissues and in colon cancer cells (71). The authors also investigated whether the inhibition of colon cancer growth by IL-32 γ was related to tumor-specific immune responses. A significantly higher number of CTLs, as well as NK cells was observed in the tumor tissues. Both IL-32 β and IL-32 γ play a role as anti-tumor cytokines.

One study tested the possibility of whether IL-32 could be developed as an anti-tumor drug. To evaluate the anti-tumor effect of IL-32 gene therapy, CMS4 sarcoma-bearing Balb/c mice were established and they were received intratumoral injections of syngeneic DCs engineered to overexpress human IL-32 β . IL-32 β -overexpressing DCs more potently activated the type 1 T cell responses *in vitro* and *in vivo*, leading to CTL-dependent suppression of tumor growth, which was independent of CD4⁺ T and NK cells (72). Contrary to the xenograft model using IL-32 β -overexpressing SW610 and PC3 cells, the activity of NK cells was not affected. Thus, IL-32 could have a selectivity for CTL or NK cells to exert anti-tumor activity in a context-dependent manner. Collectively, IL-32 directly inhibits tumor cell growth via inhibition of NF- κ B and STAT3 in tumor cells, recruits anti-tumor immune cells, including NK cells and CTLs, and also directly regulates the cytolytic activity of NK cells via increases in activating ligand and death-inducing ligands.

IL-32 stimulates differentiation of immune suppressor cells

Ohmatsu *et al.* showed that IL-32 was highly expressed in MF lesions and accelerated the induction of CD11c⁺ mature DCs (mDCs) and CD163⁺CD68⁺ macrophages (M Φ) from monocytes. The differentiated cells expressed immunosuppressive indoleamine 2, 3-dioxygenase (IDO) and IL-32. On the other hand, increased expression of IL-10 across MF lesions was highly correlated with IL-32 and IDO, but not with Foxp3

expression. Thus, in addition to a stimulatory effect on tumor proliferation, upregulated IL-32 in MF lesions might foster an immuno-tolerogenic environment by induction of immuno-suppressive mDCs or M Φ by increasing immunosuppressors, such as IL-10 and IDO (73). Effects of IL-32 on the recruitment of NK cells and CTLs, and differentiation of immune suppressor cells in the tumor microenvironment are described in Fig. 3B.

EFFECT OF IL-32 ON STEM CELLS

It is well known that octamer-binding transcription factor 4 (OCT4) expression, one of stemness factors, is increased in cancer stem cell (CSC)-like cancer cells and enhances CSC-like characteristics, including sphere formation, cell colony formation, cell migration, invasiveness, and drug resistance. Patient-derived CRCs enforced to express OCT4 resulted in high expression of IL-8 and IL-32. Neutralization of either IL-8 or IL-32 in those CRCs partially inhibited the tumorigenic effects exerted by OCT4 overexpression. Altogether, these data indicate that IL-32 affects the regulation of CSC-like properties with IL-18, through both autocrine and paracrine manners (74). To further expand on this concept, more patient-derived CRCs should be established because the study developed CRCs from only two patients. Future studies should be undertaken to determine whether OCT4 is a direct transcription factor inducing IL-32, and which IL-32 isoform is associated with induction by OCT4.

In an effort to identify a new growth factor which stimulates proliferation of hematopoietic progenitor cells (HPCs), Moldenhauer *et al.* compared the gene profile of human endothelial cells (ECs) before and after IL-1 β treatment. Notably, IL-32 significantly induced the proliferation of HPCs. Furthermore, IL-32 attenuated chemotherapy-related bone marrow cytotoxicity by increasing the number of HPCs in mice (75). Thus, if we consider a report showing that IL-32 can play as an autocrine factor for cancer stemness (74), IL-32 seems to regulate the stemness of hematopoietic stem cells, too.

CONCLUSION

In various tumor cells, IL-32 is highly increased and mainly located in the cytoplasm. Presently, IL-32 β is considered the primary isoform in cancers. By thorough review of published studies on the biological roles of IL-32 in various cancers, we found several points that should be considered for further studies. First, whether the functional roles of IL-32 in cancer are dependent on cytosolic or extracellular IL-32 should be investigated. Second, it is important to elucidate the critical signal that allows IL-32 to act as a pro-tumor or anti-tumor cytokine. Third, it is important to determine whether IL-32 originates from stromal or tumor or immune cells to comprehensively understand the role of IL-32 in the formation

of tumor microenvironments.

ACKNOWLEDGEMENTS

We especially thank Professor Soo Hyun Kim (Konkuk University, Seoul, Korea) for comments that greatly improved the manuscript. This work was supported by the National Research Foundation of Korea grant funded by the Korean government, MSIT (Ministry of Science and ICT: 2016R1A2B2011683 and 2016R1A6A3A11931083), and SRC (Science Research Center) program (Cellular Heterogeneity Research Center: 2016R1A5A1011974). We apologize for missing precious works, even though the authors tried to mention all published works.

CONFLICTS OF INTEREST

The authors have no conflicting interests.

REFERENCES

- Zitvogel L, Tesniere A and Kroemer G (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. *Nat Rev Immunol* 6, 715-727
- Galon J, Costes A, Sanchez-Cabo F et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. *Science* 313, 1960-1964
- Mosmann TR, Cherwinski H, Bond MW, Giedlin MA and Coffman RL (1986) Two types of murine helper T cell clone. I. definition according to profiles of lymphokine activities and secreted proteins. *J Immunol* 136, 2348-2357
- Sakaguchi S, Miyara M, Costantino CM and Hafler DA (2010) FOXP3⁺ regulatory T cells in the human immune system. *Nat Rev Immunol* 10, 490-500
- O'Sullivan KE, Phelan JJ, O'Hanlon C, Lysaght J, O'Sullivan JN and Reynolds JV (2014) The role of inflammation in cancer of the esophagus. *Expert Rev Gastroenterol Hepatol* 8, 749-760
- Tosello-Trampont A, Surette FA, Ewald SE and Hahn YS (2017) Immunoregulatory role of NK Cells in tissue inflammation and regeneration. *Front Immunol* 8, 301
- Yadav D and Lowenfels AB (2013) The epidemiology of pancreatitis and pancreatic cancer. *Gastroenterology* 144, 1252-1261
- Freeman HJ (2008) Colorectal cancer risk in Crohn's disease. *World J Gastroenterol* 14, 1810-1811
- Warren JR (2000) Gastric pathology associated with *Helicobacter pylori*. *Gastroenterol Clin North Am* 29, 705-751
- Noto JM and Peek RM Jr (2012) *Helicobacter pylori*: an overview. *Methods Mol Biol* 921, 7-10
- Sakitani K, Hirata Y, Hayakawa Y et al (2012) Role of interleukin-32 in *Helicobacter pylori*-induced gastric inflammation. *Infect Immun* 80, 3795-3803
- Seo EH, Kang J, Kim KH et al (2008) Detection of expressed IL-32 in human stomach cancer using ELISA and immunostaining. *J Microbiol Biotechnol* 18, 1606-1612
- Khawar MB, Abbasi MH and Sheikh N (2016) IL-32: A Novel Pluripotent inflammatory interleukin, towards gastric inflammation, gastric cancer, and chronic rhino sinusitis. *Mediators Inflamm* 2016, 8413768
- Yan H, He D, Huang X et al (2018) Role of interleukin-32 in cancer biology. *Oncol Lett* 16, 41-47
- Heinhuis B, Koenders MI, van de Loo FA, Netea MG, van den Berg WB and Joosten LA (2011) Inflammation-dependent secretion and splicing of IL-32 γ in rheumatoid arthritis. *Proc Natl Acad Sci U S A* 108, 4962-4967
- Heinhuis B, Plantinga TS, Semango G et al (2016) Alternatively spliced isoforms of IL-32 differentially influence cell death pathways in cancer cell lines. *Carcinogenesis* 37, 197-205
- Sloot YJE SJ, Joosten LAB, Netea-Maier RT (2018) Insights into the role of IL-32 in cancer. *Semin Immunol* 38, 24-32
- Wang S, Chen F and Tang L (2015) IL-32 promotes breast cancer cell growth and invasiveness. *Oncol Lett* 9, 305-307
- Taguchi A, Ohmiya N, Shirai K et al (2005) Interleukin-8 promoter polymorphism increases the risk of atrophic gastritis and gastric cancer in Japan. *Cancer Epidemiol Biomarkers Prev* 14, 2487-2493
- Wang YM, Li ZX, Tang FB et al (2016) Association of genetic polymorphisms of interleukins with gastric cancer and precancerous gastric lesions in a high-risk Chinese population. *Tumour Biol* 37, 2233-2242
- Tsai CY, Wang CS, Tsai MM et al (2014) Interleukin-32 increases human gastric cancer cell invasion associated with tumor progression and metastasis. *Clin Cancer Res* 20, 2276-2288
- Ishigami S, Arigami T, Uchikado Y et al (2013) IL-32 expression is an independent prognostic marker for gastric cancer. *Med Oncol* 30, 472
- Erturk K, Tastekin D, Serilmez M, Bilgin E, Bozbey HU and Vatansver S (2006) Clinical significance of serum interleukin-29, interleukin-32, and tumor necrosis factor alpha levels in patients with gastric cancer. *Tumour Biol* 37, 405-412
- Chang WJ, Du Y, Zhao X, Ma LY and Cao GW (2014) Inflammation-related factors predicting prognosis of gastric cancer. *World J Gastroenterol* 20, 4586-4596
- Nishida A, Andoh A, Inatomi O and Fujiyama Y (2009) Interleukin-32 expression in the pancreas. *J Biol Chem* 284, 17868-17876
- van Hogezaand RA, Eichhorn RF, Choudry A, Veenendaal RA and Lamers CB (2002) Malignancies in inflammatory bowel disease: fact or fiction? *Scand J Gastroenterol Suppl*, 48-53
- Yun HM, Park KR, Kim EC, Han SB, Yoon DY and Hong JT (2015) IL-32 α suppresses colorectal cancer development via TNFR1-mediated death signaling. *Oncotarget* 6, 9061-9072
- Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S and Mori H (2003) A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. *Cancer Sci* 94, 965-973
- Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki

- Y and Nakaya R (1990) A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. *Gastroenterology* 98, 694-702
30. Yang Y, Wang Z, Zhou Y, Wang X, Xiang J and Chen Z (2015) Dysregulation of over-expressed IL-32 in colorectal cancer induces metastasis. *World J Surg Oncol* 13, 146
 31. Khawar MB, Mukhtar M, Abbasi MH, Sheikh N (2017) IL-32 α : a recently identified anti-inflammatory variant of IL-32 and its preventive role in various disorders and tumor suppressor activity. *Am J Transl Res* 9, 4726-4737
 32. Catalán V, Gómez-Ambrosi J, Rodríguez A et al (2017) IL-32 α -induced inflammation constitutes a link between obesity and colon cancer. *Oncoimmunology* 6, e1328338
 33. Sherman M and Klein A (2004) AASLD single-topic research conference on hepatocellular carcinoma: Conference proceedings. *Hepatology* 40, 1465-1473
 34. Xu H, Zhang S, Pan X et al (2016) TIMP-1 expression induced by IL-32 is mediated through activation of AP-1 signal pathway. *Int Immunopharmacol* 38, 233-237
 35. Kim SH, Han SY, Azam T, Yoon DY and Dinarello CA (2005) Interleukin-32: a cytokine and inducer of TNF α . *Immunity* 22, 131-142
 36. Kudo M, Ogawa E, Kinose D et al (2012) Oxidative stress induced interleukin-32 mRNA expression in human bronchial epithelial cells. *Respir Res* 13, 19
 37. Dinarello CA and Kim SH (2006) IL-32, a novel cytokine with a possible role in disease. *Ann Rheum Dis* 65 Suppl 3, iii61-64
 38. Pan X, Cao H, Lu J et al (2011) Interleukin-32 expression induced by hepatitis B virus protein X is mediated through activation of NF- κ B. *Mol Immunol* 48, 1573-1577
 39. Moschen AR, Fritz T, Clouston AD et al (2011) Interleukin-32: a new proinflammatory cytokine involved in hepatitis C virus-related liver inflammation and fibrosis. *Hepatology* 53, 1819-1829
 40. Kang YH, Park MY, Yoon DY et al (2012) Dysregulation of overexpressed IL-32 α in hepatocellular carcinoma suppresses cell growth and induces apoptosis through inactivation of NF- κ B and Bcl-2. *Cancer Lett* 318, 226-233
 41. Zhao WB, Wang QL, Xu YT, Xu SF, Qiu Y, Zhu F (2018) Overexpression of interleukin-32 α promotes invasion by modulating VEGF in hepatocellular carcinoma. *Oncol Rep.* 39, 1155-1162
 42. Iliaz R, Akyuz U, Tekin D et al (2016) Role of several cytokines and adhesion molecules in the diagnosis and prediction of survival of hepatocellular carcinoma. *Arab J Gastroenterol* 17, 164-167
 43. Kim DH, Park ES, Lee AR et al (2018) Intracellular interleukin-32 γ mediates antiviral activity of cytokines against hepatitis B virus. *Nat Commun* 9, 3284
 44. Sato M, Shames DS, Gazdar AF and Minna JD (2007) A translational view of the molecular pathogenesis of lung cancer. *J Thorac Oncol* 2, 327-343
 45. Zeng Q, Li S, Zhou Y et al (2013) Interleukin-32 contributes to invasion and metastasis of primary lung adenocarcinoma via NF- κ B induced matrix metalloproteinases 2 and 9 expression. *Cytokine* 65, 24-32
 46. Sorrentino C and Di Carlo E (2009) Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype. *Am J Respir Crit Care Med* 180, 769-779
 47. Wang Y, Yang Y, Zhu Y, Li L, Chen F and Zhang L (2017) Polymorphisms and expression of IL-32: impact on genetic susceptibility and clinical outcome of lung cancer. *Biomarkers* 22, 165-170
 48. Yun J, Park MH, Son DJ et al (2018) IL-32 γ reduces lung tumor development through upregulation of TIMP-3 overexpression and hypomethylation. *Cell Death Dis* 9, 306
 49. Park JS, Choi SY, Lee JH et al (2013) Interleukin-32 β stimulates migration of MDA-MB-231 and MCF-7 cells via the VEGF-STAT3 signaling pathway. *Cell Oncol (Dordr)* 36, 493-503
 50. Park JS, Lee S, Jeong AL et al (2014) Hypoxia-induced IL-32 β increases glycolysis in breast cancer cells. *Cancer Lett* 356, 800-808
 51. Ainscough JS, Frank Gerberick G, Zahedi-Nejad M et al (2014) Dendritic cell IL-1 α and IL-1 β are polyubiquitinated and degraded by the proteasome. *J Biol Chem* 289, 35582-35592
 52. Yong HJ, Park JS, Lee Jeong A et al (2017) Von Hippel-Lindau regulates interleukin-32 β stability in ovarian cancer cells. *Oncotarget* 8, 69833-69846
 53. Ternette N, Olde Nordkamp MJM, Muller J et al (2018) Immunopeptidomic profiling of HLA-A2-positive triple negative breast cancer identifies potential immunotherapy target antigens. *Proteomics* 18, e1700465
 54. Lee S, Kim JH, Kim H et al (2010) Activation of the interleukin-32 pro-inflammatory pathway in response to human papillomavirus infection and over-expression of interleukin-32 controls the expression of the human papillomavirus oncogene. *Immunology* 132, 410-420
 55. Lee S, Kim H, Kang JW et al (2011) The biflavonoid amentoflavone induces apoptosis via suppressing E7 expression, cell cycle arrest at sub-G(1) phase, and mitochondria-emanated intrinsic pathways in human cervical cancer cells. *J Med Food* 14, 808-816
 56. Goda C, Kanaji T, Kanaji S et al (2006) Involvement of IL-32 in activation-induced cell death in T cells. *Int Immunol* 18, 233-240
 57. Zhang F, Suarez G, Sha J, Sierra JC, Peterson JW and Chopra AK (2009) Phospholipase A2-activating protein (PLAA) enhances cisplatin-induced apoptosis in HeLa cells. *Cell Signal* 21, 1085-1099
 58. Cui Y, Sun Z, Li X et al (2016) Expression and clinical significance of cyclooxygenase-2 and interleukin-32 in primary gastric B-cell lymphoma. *Oncol Lett* 11, 693-698
 59. Yamac D, Ayyildiz T, Coskun U et al (2008) Cyclooxygenase-2 expression and its association with angiogenesis, *Helicobacter pylori*, and clinicopathologic characteristics of gastric carcinoma. *Pathol Res Pract* 204, 527-536
 60. Konturek PC, Hartwich A, Zuchowicz M et al (2000) *Helicobacter pylori*, gastrin and cyclooxygenases in gastric cancer. *J Physiol Pharmacol* 51, 737-749
 61. Lee S, Kim JH, Kim H et al (2011) Activation of the interleukin-32 pro-inflammatory pathway in response to human papillomavirus infection and over-expression of interleukin-32 controls the expression of the human

- papillomavirus oncogene. *Immunology* 132, 410-420
62. van Kester MS, Borg MK, Zoutman WH et al (2012) A meta-analysis of gene expression data identifies a molecular signature characteristic for tumor-stage mycosis fungoides. *J Invest Dermatol* 132, 2050-2059
 63. Suga H, Sugaya M, Miyagaki T et al (2013) The role of IL-32 in cutaneous T-cell lymphoma. *J Invest Dermatol* 134, 1428-1435
 64. Cheon S, Lee JH, Park S et al (2011) Overexpression of IL-32alpha increases natural killer cell-mediated killing through up-regulation of Fas and UL16-binding protein 2 (ULBP2) expression in human chronic myeloid leukemia cells. *J Biol Chem* 286, 12049-12055
 65. Raulet DH (2003) Roles of the NKG2D immunoreceptor and its ligands. *Nat Rev Immunol* 3, 781-790
 66. Jamieson AM, Diefenbach A, McMahon CW, Xiong N, Carlyle JR and Raulet DH (2002) The role of the NKG2D immunoreceptor in immune cell activation and natural killing. *Immunity* 17, 19-29
 67. Park MH, Song MJ, Cho MC et al (2011) Interleukin-32 enhances cytotoxic effect of natural killer cells to cancer cells via activation of death receptor 3. *Immunology* 135, 63-72
 68. Smyth MJ, Cretney E, Takeda K et al (2001) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. *J Exp Med* 193, 661-670
 69. Screpanti V, Wallin RP, Grandien A and Ljunggren HG (2005) Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells. *Mol Immunol* 42, 495-499
 70. Yun HM, Oh JH, Shim JH et al (2013) Antitumor activity of IL-32beta through the activation of lymphocytes, and the inactivation of NF-kappaB and STAT3 signals. *Cell Death Dis* 4, e640
 71. Oh JH, Cho MC, Kim JH et al (2011) IL-32gamma inhibits cancer cell growth through inactivation of NF-kappaB and STAT3 signals. *Oncogene* 30, 3345-3359
 72. Qu Y, Taylor JL, Bose A and Storkus WJ (2011) Therapeutic effectiveness of intratumorally delivered dendritic cells engineered to express the pro-inflammatory cytokine, interleukin (IL)-32. *Cancer Gene Ther* 18, 663-673
 73. Ohmatsu H, Humme D, Gonzalez J et al (2017) IL-32 induces indoleamine 2,3-dioxygenase+CD1c+ dendritic cells and indoleamine 2,3-dioxygenase+CD163+ macrophages: Relevance to mycosis fungoides progression. *Oncoimmunology* 6, e1181237
 74. Chang CJ, Chien Y, Lu KH et al (2011) Oct4-related cytokine effects regulate tumorigenic properties of colorectal cancer cells. *Biochem Biophys Res Commun* 415, 245-251
 75. Moldenhauer A, Futschik M, Lu H et al (2011) Interleukin 32 promotes hematopoietic progenitor expansion and attenuates bone marrow cytotoxicity. *Eur J Immunol* 41, 1774-1786